Flotetuzumab
From Wikipedia, the free encyclopedia
| Monoclonal antibody | |
|---|---|
| Type | Di-single-chain variable fragment |
| Source | Humanized (from mouse) |
| Target | CD3, CD123 |
| Clinical data | |
| Other names | MGD006 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C2618H4040N704O813S16 |
| Molar mass | 58898.19 g·mol−1 |
Flotetuzumab (INN;[1] development code MGD006) is a bispecific antibody[2] designed for the treatment of acute myeloid leukemia.[3][4]
This drug is being developed by MacroGenics, Inc.[5]
